世界の更年期治療・血管運動症状市場予測(~2025年)

• 英文タイトル:Global Vasomotor Symptoms of Menopause Treatment Market 2020 by Company, Regions, Type and Application, Forecast to 2025

Global Vasomotor Symptoms of Menopause Treatment Market 2020 by Company, Regions, Type and Application, Forecast to 2025「世界の更年期治療・血管運動症状市場予測(~2025年)」(市場規模、市場予測)調査レポートです。• レポートコード:GIR201115349
• 出版社/出版日:GlobalInfoResearch / 2020年10月
• レポート形態:英文、PDF、109ページ
• 納品方法:Eメール
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥379,320 (USD3,480)▷ お問い合わせ
  Multi User¥568,980 (USD5,220)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本書では、更年期治療・血管運動症状の世界市場を調査対象にし、更年期治療・血管運動症状の市場概要、企業情報、企業別売上・市場シェア、地域別市場分析(北米、アメリカ、ヨーロッパ、アジア、日本、中国、南米、中東・アフリカ)、種類別分析(エステトロール、フェゾリネタント、FP-101、HBN-2、その他)、用途別分析(病院、在宅医療、クリニック)、市場予測(2021年~2025年)情報などを整理しました。
・市場概要
・企業情報:Amgen Inc.、Radius Health, Inc.、MenoGeniX, Inc.、EndoCeutics, Inc.、Pivot Pharmaceuticals Inc、Euroscreen S.A.、Pherin Pharmaceuticals, Inc.、Mithra Pharmaceuticals S.A.、TherapeuticsMD, Inc.
・企業別売上、市場シェア
・更年期治療・血管運動症状の地域別市場分析
・更年期治療・血管運動症状の北米市場規模2015-2020:アメリカ、カナダ、メキシコ
・更年期治療・血管運動症状のヨーロッパ市場規模2015-2020:ドイツ、イギリス、フランス、ロシアなど
・更年期治療・血管運動症状のアジア市場規模2015-2020:日本、中国、韓国、インド、東南アジアなど
・更年期治療・血管運動症状の南米市場規模2015-2020:ブラジル、アルゼンチンなど
・更年期治療・血管運動症状の中東・アフリカ市場規模2015-2020:サウジアラビア、トルコ、エジプト、南アフリカなど
・更年期治療・血管運動症状の種類別市場規模2015-2020:エステトロール、フェゾリネタント、FP-101、HBN-2、その他
・更年期治療・血管運動症状の用途別市場規模2015-2020:病院、在宅医療、クリニック
・更年期治療・血管運動症状の世界市場予測2021-2025:地域別、種類別、用途別
・調査の結果・結論

Market Overview
The global Vasomotor Symptoms of Menopause Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

The Vasomotor Symptoms of Menopause Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Vasomotor Symptoms of Menopause Treatment market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Vasomotor Symptoms of Menopause Treatment market has been segmented into:
Estetrol
Fezolinetant
FP-101
HBN-2
Others

By Application, Vasomotor Symptoms of Menopause Treatment has been segmented into:
Hospital
Homecare
Clinic

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Vasomotor Symptoms of Menopause Treatment market presented in the report. This section sheds light on the sales growth of different regional and country-level Vasomotor Symptoms of Menopause Treatment markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Vasomotor Symptoms of Menopause Treatment market.

The report offers in-depth assessment of the growth and other aspects of the Vasomotor Symptoms of Menopause Treatment market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Vasomotor Symptoms of Menopause Treatment Market Share Analysis
Vasomotor Symptoms of Menopause Treatment competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Vasomotor Symptoms of Menopause Treatment sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Vasomotor Symptoms of Menopause Treatment sales, revenue and market share for each player covered in this report.

The major players covered in Vasomotor Symptoms of Menopause Treatment are:
Amgen Inc.
Radius Health, Inc.
MenoGeniX, Inc.
EndoCeutics, Inc.
Pivot Pharmaceuticals Inc
Euroscreen S.A.
Pherin Pharmaceuticals, Inc.
Mithra Pharmaceuticals S.A.
TherapeuticsMD, Inc.

レポート目次

Table of Contents

1 Vasomotor Symptoms of Menopause Treatment Market Overview
1.1 Product Overview and Scope of Vasomotor Symptoms of Menopause Treatment
1.2 Classification of Vasomotor Symptoms of Menopause Treatment by Type
1.2.1 Global Vasomotor Symptoms of Menopause Treatment Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Type in 2019
1.2.3 Estetrol
1.2.4 Fezolinetant
1.2.5 FP-101
1.2.6 HBN-2
1.2.7 Others
1.3 Global Vasomotor Symptoms of Menopause Treatment Market by Application
1.3.1 Overview: Global Vasomotor Symptoms of Menopause Treatment Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital
1.3.3 Homecare
1.3.4 Clinic
1.4 Global Vasomotor Symptoms of Menopause Treatment Market by Regions
1.4.1 Global Vasomotor Symptoms of Menopause Treatment Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Vasomotor Symptoms of Menopause Treatment (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Vasomotor Symptoms of Menopause Treatment Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Vasomotor Symptoms of Menopause Treatment Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Vasomotor Symptoms of Menopause Treatment Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Vasomotor Symptoms of Menopause Treatment Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Vasomotor Symptoms of Menopause Treatment Status and Prospect (2015-2025)
2 Company Profiles
2.1 Amgen Inc.
2.1.1 Amgen Inc. Details
2.1.2 Amgen Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Amgen Inc. SWOT Analysis
2.1.4 Amgen Inc. Product and Services
2.1.5 Amgen Inc. Vasomotor Symptoms of Menopause Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.2 Radius Health, Inc.
2.2.1 Radius Health, Inc. Details
2.2.2 Radius Health, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Radius Health, Inc. SWOT Analysis
2.2.4 Radius Health, Inc. Product and Services
2.2.5 Radius Health, Inc. Vasomotor Symptoms of Menopause Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.3 MenoGeniX, Inc.
2.3.1 MenoGeniX, Inc. Details
2.3.2 MenoGeniX, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 MenoGeniX, Inc. SWOT Analysis
2.3.4 MenoGeniX, Inc. Product and Services
2.3.5 MenoGeniX, Inc. Vasomotor Symptoms of Menopause Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.4 EndoCeutics, Inc.
2.4.1 EndoCeutics, Inc. Details
2.4.2 EndoCeutics, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 EndoCeutics, Inc. SWOT Analysis
2.4.4 EndoCeutics, Inc. Product and Services
2.4.5 EndoCeutics, Inc. Vasomotor Symptoms of Menopause Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.5 Pivot Pharmaceuticals Inc
2.5.1 Pivot Pharmaceuticals Inc Details
2.5.2 Pivot Pharmaceuticals Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Pivot Pharmaceuticals Inc SWOT Analysis
2.5.4 Pivot Pharmaceuticals Inc Product and Services
2.5.5 Pivot Pharmaceuticals Inc Vasomotor Symptoms of Menopause Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.6 Euroscreen S.A.
2.6.1 Euroscreen S.A. Details
2.6.2 Euroscreen S.A. Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Euroscreen S.A. SWOT Analysis
2.6.4 Euroscreen S.A. Product and Services
2.6.5 Euroscreen S.A. Vasomotor Symptoms of Menopause Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.7 Pherin Pharmaceuticals, Inc.
2.7.1 Pherin Pharmaceuticals, Inc. Details
2.7.2 Pherin Pharmaceuticals, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Pherin Pharmaceuticals, Inc. SWOT Analysis
2.7.4 Pherin Pharmaceuticals, Inc. Product and Services
2.7.5 Pherin Pharmaceuticals, Inc. Vasomotor Symptoms of Menopause Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.8 Mithra Pharmaceuticals S.A.
2.8.1 Mithra Pharmaceuticals S.A. Details
2.8.2 Mithra Pharmaceuticals S.A. Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Mithra Pharmaceuticals S.A. SWOT Analysis
2.8.4 Mithra Pharmaceuticals S.A. Product and Services
2.8.5 Mithra Pharmaceuticals S.A. Vasomotor Symptoms of Menopause Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.9 TherapeuticsMD, Inc.
2.9.1 TherapeuticsMD, Inc. Details
2.9.2 TherapeuticsMD, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 TherapeuticsMD, Inc. SWOT Analysis
2.9.4 TherapeuticsMD, Inc. Product and Services
2.9.5 TherapeuticsMD, Inc. Vasomotor Symptoms of Menopause Treatment Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Vasomotor Symptoms of Menopause Treatment Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Vasomotor Symptoms of Menopause Treatment Players Market Share
3.2.2 Top 10 Vasomotor Symptoms of Menopause Treatment Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Vasomotor Symptoms of Menopause Treatment Revenue and Market Share by Regions
4.2 North America Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
4.3 Europe Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
4.5 South America Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
5 North America Vasomotor Symptoms of Menopause Treatment Revenue by Countries
5.1 North America Vasomotor Symptoms of Menopause Treatment Revenue by Countries (2015-2020)
5.2 USA Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
5.3 Canada Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
5.4 Mexico Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
6 Europe Vasomotor Symptoms of Menopause Treatment Revenue by Countries
6.1 Europe Vasomotor Symptoms of Menopause Treatment Revenue by Countries (2015-2020)
6.2 Germany Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
6.3 UK Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
6.4 France Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
6.5 Russia Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
6.6 Italy Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Vasomotor Symptoms of Menopause Treatment Revenue by Countries
7.1 Asia-Pacific Vasomotor Symptoms of Menopause Treatment Revenue by Countries (2015-2020)
7.2 China Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
7.3 Japan Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
7.4 Korea Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
7.5 India Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
8 South America Vasomotor Symptoms of Menopause Treatment Revenue by Countries
8.1 South America Vasomotor Symptoms of Menopause Treatment Revenue by Countries (2015-2020)
8.2 Brazil Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
8.3 Argentina Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Vasomotor Symptoms of Menopause Treatment by Countries
9.1 Middle East & Africa Vasomotor Symptoms of Menopause Treatment Revenue by Countries (2015-2020)
9.2 Saudi Arabia Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
9.3 UAE Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
9.4 Egypt Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
9.5 South Africa Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Vasomotor Symptoms of Menopause Treatment Revenue and Market Share by Type (2015-2020)
10.2 Global Vasomotor Symptoms of Menopause Treatment Market Forecast by Type (2019-2024)
10.3 Estetrol Revenue Growth Rate (2015-2025)
10.4 Fezolinetant Revenue Growth Rate (2015-2025)
10.5 FP-101 Revenue Growth Rate (2015-2025)
10.6 HBN-2 Revenue Growth Rate (2015-2025)
10.7 Others Revenue Growth Rate (2015-2025)
11 Global Vasomotor Symptoms of Menopause Treatment Market Segment by Application
11.1 Global Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Application (2015-2020)
11.2 Vasomotor Symptoms of Menopause Treatment Market Forecast by Application (2019-2024)
11.3 Hospital Revenue Growth (2015-2020)
11.4 Homecare Revenue Growth (2015-2020)
11.5 Clinic Revenue Growth (2015-2020)
12 Global Vasomotor Symptoms of Menopause Treatment Market Size Forecast (2021-2025)
12.1 Global Vasomotor Symptoms of Menopause Treatment Market Size Forecast (2021-2025)
12.2 Global Vasomotor Symptoms of Menopause Treatment Market Forecast by Regions (2021-2025)
12.3 North America Vasomotor Symptoms of Menopause Treatment Revenue Market Forecast (2021-2025)
12.4 Europe Vasomotor Symptoms of Menopause Treatment Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Vasomotor Symptoms of Menopause Treatment Revenue Market Forecast (2021-2025)
12.6 South America Vasomotor Symptoms of Menopause Treatment Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Vasomotor Symptoms of Menopause Treatment Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US




• 英文レポート名:Global Vasomotor Symptoms of Menopause Treatment Market 2020 by Company, Regions, Type and Application, Forecast to 2025
• 日本語訳:世界の更年期治療・血管運動症状市場予測(~2025年)
• レポートコード:GIR201115349お問い合わせ(見積依頼・ご注文・質問)